Innovation & Research

Creating Tomorrow’s Therapies Today

Minnesota Urology physicians conduct a variety of clinical studies to bring the safest and most effective new urologic products and therapies to men and women suffering from urologic conditions.   

Research That Makes a Difference

At Minnesota Urology, we conduct a variety of clinical studies, from observational studies to large, randomized, controlled interventional clinical trials. We conduct Phase II and Phase III clinical trials that are especially important for getting new treatment options approved for clinical care. Our goal is to make a difference in the lives of our patients, both today and tomorrow.

STUDIES CURRENTLY OPEN FOR
ENROLLMENT OF ELIGIBLE PATIENTS

For more information or to determine if you may be eligible, call Clinical Research at 651-999-7032.

Recurrent Urethral Stricture

Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease – A Randomized Controlled Trial (ROBUST III Clinical Study)

  • A prospective, multi-center, single-blinded, randomized, controlled clinical device trial being conducted in males with a recurrent urethral stricture to establish the safety and effectiveness of the Urotronic Optilume drug-coated balloon.

 

Urinary Urgency Incontinence

Clinical Study of Neuspera’s Implantable Sacral Nerve Stimulation (SNS) System in Patients with Symptoms of Overactive Bladder

  • A prospective, multi-center, pivotal study investigating the Neuspera implantable sacral nerve stimulation (SNS device) in male and female patients diagnosed with urinary urgency incontinence who have failed or could not tolerate more conservative treatment. This study is being conducted in two separate phases. Phase 1 objective: To assess the use of the implanted Neuspera SNS device during a trial period to help inform the length of hours of daily stimulation to be used in Phase 2 of the trial. Phase 2 objective: To assess the safety and efficacy of the implanted Neuspera SNS system among study participants receiving the duration of device stimulation each day as determined in Phase 1 of the study.

 

Urinary Urgency Incontinence

Sacral Neuromodulation Phase 2 Study

  • A prospective, multi-center, single-arm study to assess the feasibility of stimulating the sacral nerve using a pattern of variable amplitude pulses up to the sensory threshold to treat symptoms associated with urinary incontinence in female patients who are candidates for Medtronic InterStim lead placement.

 

Overactive Bladder with Urinary Urgency Incontinence and/or Urinary Frequency

Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study

  • A prospective, multi-center, post-market clinical follow-up study for the continued assessment of safety and performance of the Medtronic InterStim Basic Evaluation Lead during a sacral neuromodulation therapy evaluation in male and female patients with a diagnosis of overactive bladder with urinary urgency incontinence and/or urinary frequency.

 

Metastatic, Castration-resistant Prostate Cancer

A Real-World Observational Study to Provide Prospective Information on the Management of Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) with Disease Progression After at Least one Line of Androgen Receptor-targeted Therapy (ARTT) and the Use of the Oncotype DX AR-V7 Nucleus Detect® Assay in Subsequent Management

  • A prospective, observational study to characterize the natural history, treatment patterns and impact of the Oncotype DX AR-V7 Nucleus Detect testing on physician treatment choices in high-risk men with metastatic castration-resistant prostate cancer with disease progression who have previously received at least one line of androgen receptor-targeted drug therapy (e.g., apalutamide, enzalutamide or abiraterone).

Help Us Foster Innovation

Minnesota Urology welcomes participants in its clinical studies. Advancements in clinical care are made possible through patient volunteers who participate in clinical research. By participating in one of our studies, patients may have access to new and innovative treatments not otherwise available. Depending on the study, they also may be eligible to receive testing, treatment, and other clinical services at no cost, as well as study patient stipends and travel compensation. For more information or to determine if you may be eligible, call Clinical Research at 651-999-7032.

Skip to toolbar